PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
MNPR vs. ^GSPC
Performance
Risk-Adjusted Performance
Drawdowns
Volatility

Correlation

The correlation between MNPR and ^GSPC is 0.12, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

MNPR vs. ^GSPC

Last updated Jun 1, 2025

Compare and contrast key facts about Monopar Therapeutics Inc. (MNPR) and S&P 500 (^GSPC).

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: MNPR or ^GSPC.

Performance

MNPR vs. ^GSPC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Monopar Therapeutics Inc. (MNPR) and S&P 500 (^GSPC). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

MNPR:

1.53

^GSPC:

0.66

Sortino Ratio

MNPR:

8.16

^GSPC:

0.94

Omega Ratio

MNPR:

2.12

^GSPC:

1.14

Calmar Ratio

MNPR:

9.39

^GSPC:

0.60

Martin Ratio

MNPR:

30.23

^GSPC:

2.28

Ulcer Index

MNPR:

30.55%

^GSPC:

5.01%

Daily Std Dev

MNPR:

622.69%

^GSPC:

19.77%

Max Drawdown

MNPR:

-98.93%

^GSPC:

-56.78%

Current Drawdown

MNPR:

-76.50%

^GSPC:

-3.78%

Returns By Period

In the year-to-date period, MNPR achieves a 44.23% return, which is significantly higher than ^GSPC's 0.51% return.

MNPR

YTD

44.23%

1M

-26.47%

6M

40.83%

1Y

938.63%

3Y*

43.67%

5Y*

-3.79%

10Y*

N/A

^GSPC

YTD

0.51%

1M

5.49%

6M

-2.00%

1Y

12.02%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Monopar Therapeutics Inc.

S&P 500

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

MNPR vs. ^GSPC — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
MNPR
The Risk-Adjusted Performance Rank of MNPR is 9898
Overall Rank
The Sharpe Ratio Rank of MNPR is 9090
Sharpe Ratio Rank
The Sortino Ratio Rank of MNPR is 9999
Sortino Ratio Rank
The Omega Ratio Rank of MNPR is 9999
Omega Ratio Rank
The Calmar Ratio Rank of MNPR is 100100
Calmar Ratio Rank
The Martin Ratio Rank of MNPR is 9999
Martin Ratio Rank
^GSPC
The Risk-Adjusted Performance Rank of ^GSPC is 6363
Overall Rank
The Sharpe Ratio Rank of ^GSPC is 6262
Sharpe Ratio Rank
The Sortino Ratio Rank of ^GSPC is 5959
Sortino Ratio Rank
The Omega Ratio Rank of ^GSPC is 6262
Omega Ratio Rank
The Calmar Ratio Rank of ^GSPC is 6363
Calmar Ratio Rank
The Martin Ratio Rank of ^GSPC is 6969
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

MNPR vs. ^GSPC - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Monopar Therapeutics Inc. (MNPR) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current MNPR Sharpe Ratio is 1.53, which is higher than the ^GSPC Sharpe Ratio of 0.66. The chart below compares the historical Sharpe Ratios of MNPR and ^GSPC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Drawdowns

MNPR vs. ^GSPC - Drawdown Comparison

The maximum MNPR drawdown since its inception was -98.93%, which is greater than ^GSPC's maximum drawdown of -56.78%. Use the drawdown chart below to compare losses from any high point for MNPR and ^GSPC.

Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

MNPR vs. ^GSPC - Volatility Comparison

Monopar Therapeutics Inc. (MNPR) has a higher volatility of 26.05% compared to S&P 500 (^GSPC) at 4.77%. This indicates that MNPR's price experiences larger fluctuations and is considered to be riskier than ^GSPC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading data...